Cargando…
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia
FLT3-ITD mutations in newly diagnosed acute myeloid leukemia (AML) are associated with worse overall survival (OS). FLT3-ITD diversity can further influence clinical outcomes. Addition of FLT3 inhibitors to standard chemotherapy has improved OS. The aim of this study is to evaluate the prognostic im...
Autores principales: | Abou Dalle, Iman, Ghorab, Ahmad, Patel, Keyur, Wang, Xuemei, Hwang, Hyunsoo, Cortes, Jorge, Issa, Ghayas C., Yalniz, Fevzi, Sasaki, Koji, Chihara, Dai, Price, Allyson, Kadia, Tapan, Pemmaraju, Naveen, Daver, Naval, DiNardo, Courtney, Ravandi, Farhad, Kantarjian, Hagop M., Borthakur, Gautam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198530/ https://www.ncbi.nlm.nih.gov/pubmed/32366841 http://dx.doi.org/10.1038/s41408-020-0318-1 |
Ejemplares similares
-
Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022) -
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
por: Maiti, Abhishek, et al.
Publicado: (2021) -
Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series
por: Alotaibi, Ahmad S., et al.
Publicado: (2020) -
Resistance to targeted therapies: delving into FLT3 and IDH
por: Desikan, Sai Prasad, et al.
Publicado: (2022) -
Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021)